Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$9.81
-0.28 (-2.78%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 24%
FCF escenarios
weak_data · normalized FCF $16.0M · quality 46.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.8B
P/E
37.7x
↑EV/EBITDA
19.4x
↑ROE
7.8%
↑Gross Margin
34.9%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.3%
FCF CAGR
+22.3%
FCF margin
2.3%
FCF / Net income
0.13x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $672.4M · net income $121.2M · FCF $15.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $672.4M | $672.4M | $726.4M | $651.4M | $627.4M |
| Net Income | $121.2M | $121.2M | $173.6M | $159.0M | $132.3M |
| EBITDA | $189.8M | $189.8M | $235.3M | $212.4M | $174.0M |
| EPS | 0.31 | 0.31 | 0.44 | 0.41 | 0.44 |
| Gross Margin | 34.9% | 34.9% | 40.6% | 39.8% | 35.6% |
| Operating Margin | 19.8% | 19.8% | 26.3% | 24.6% | 23.8% |
| Net Margin | 18.0% | 18.0% | 23.9% | 24.4% | 21.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 6.35 | 6.35 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $15.6M | $15.6M | $16.0M | $162.9M | $8.5M |
| Returns | |||||
| ROE | 7.8% | 7.8% | 11.3% | 11.0% | 9.8% |
| Valuation | |||||
| P/E | 37.73 | 37.73 | 21.69 | 25.71 | 22.46 |
| EV/EBITDA | 19.35 | 19.35 | 14.82 | 17.99 | 16.81 |
| P/B | 2.47 | 2.47 | 2.44 | 2.82 | 2.19 |
| Growth & Yield | |||||
| Revenue Growth | -7.4% | -7.4% | 11.5% | 3.8% | — |
| EPS Growth | -29.5% | -29.5% | 8.1% | -7.2% | — |
| Dividend Yield | 2.0% | 2.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
41.1%
EPS terminal req.
$0.87
Spread vs growth
-70.6%
5Y implied EPS CAGR
27.7%
EPS terminal req.
$1.05
Spread vs growth
-57.3%
10Y implied EPS CAGR
18.5%
EPS terminal req.
$1.70
Spread vs growth
-48.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-24.0%
Start / end P/E
30.1x → 31.6x
EPS bridge
0.44 → 0.31
Residual
-1.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.